Case Studies in Treatment Resistant Depression
Up to 1.25 AMA PRA Category 1 Credits™
Release Date: December 31, 2012
Expiration Date: December 31, 2013
Estimated Time to Complete this Activity: 1.25 hours
This initiative has been developed for psychiatrists and other healthcare professionals caring for those with depression.
Statement of Purpose
There is only limited information about how to successfully treat people with depression, especially how to treat people with depression who have not improved with the first treatment tried. It is estimated that 10-30% of patients with MDD do not respond to initial therapy. Depression is considered â€œtreatment-resistantâ€ when there is no response to at least two adequately delivered courses of treatment. Any failure of initial antidepressant treatments may question the adequacy of the treatment itself.
Successfully managing treatment resistant depression requires a careful and committed physician and care team that has developed a trusting rapport with the patient. Despite the difficulties these patients can achieve remission of symptoms and may be maintained to restore normal function and quality of life.
This CME activity will explore accurately diagnosing, achieving remission and continued management for patients with treatment resistant major depressive disorder.
Upon completion of this activity, you should be able to:
- Recognize the prevalence of treatment-resistant major depressive disorder and the burden on patients and families.
- Assess and adopt American Psychiatric Association guidelines for the management of depression.
- Contrast and compare the efficacy and safety of various treatment options for patients with treatment-resistant depression
- Employ effective techniques of communication in order to improve adherence for patients on antidepressant treatment regimens.
This activity will iclude discussion around three patient cases derived from patients seen in practice.
Each case will demonstarte elements of treatment resistant depression.
- Case 1: 24 Year Old Female
- Case 2: 56 Year Old Hispanic Female
- Case 3: 45 Year Old Male with long history of illness
Ira Lesser, MD
Chair, Department of Psychiatry, Harbor-UCLA Medical Center; Professor, Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at UCLA
Andrew Leuchter, MD
Professor, Department of Psychiatry and Biobehavioral Science; Director, Laboratory of Brain, Behavior, and Pharmacology; Senior Research Scientist, UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA
Sidney Zisook, MD
Professor, Department of Psychiatry, University of California; Director, Residency Training Program, Department of Psychiatry, University of California, San Diego, CA
Michael Fleming, MD, FAAFP
Assistant Clinical Professor of Family Medicine and Comprehensive Care at LSU Health Science Center School of Medicine in Shreveport, and Assistant Clinical Professor of Family Medicine in the Department of Family and Community Medicine at Tulane University Medical School. Chief Medical Officer, Antidote Education Company & Amedisys, Inc.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Antidote Education Company and Performance Healthcare Initiative. Antidote is accredited by the ACCME to provide continuing medical education for physicians.
Antidote Education Company designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Creditsâ„¢. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This CME activity is supported by an unrestricted educational grant from Bristol-Myers Squibb.
Method of Participation
- Read the learning objectives and faculty disclosures.
- Click on the link below to participate in the online activity. Answer any questions presented.
- Complete the post-test and evaluation presented at the end of the activity.
Please complete the evaluation form, which provides each participant with the opportunity to comment on the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and his/her views on future educational needs. A score of at least 70% is required to successfully complete this activity. The participant must pass the post test within 3 attempts. Credit is available through December 31, 2013.
Antidote is committed to creating, developing, and operating high-quality, relevant, and practical continuing medical education activities that are in compliance with the ACCME's policies on commercial support and disclosure. Specifically, we are dedicated to ensuring that our events are planned and implemented free of the control of commercial interests and to identifying and resolving conflicts of interest of all persons in a position to control the content of an educational activity before the educational activity is delivered to our attendees. In addition, it is our standard practice to disclose all relevant financial relationships of our speakers in writing to our attendees before the beginning of an educational activity.
Individuals in a position to control the content of this CME activity reported the following relevant financial relationships with commercial interests:
Dr. Zisook - Research support from Pam Labs
Consultant - Aspect Medical Systems, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Otsuka Pharmaceuticals, and Pfizer.
Speaker's Bureau - Bristol-Myers Squibb, Eli Lilly and Company, Otsuka Pharmaceuticals, and Wyeth-Ayerst Pharmaceuticals.
Research - Aspect Medical Systems, Eli Lilly and Company, Wyeth-Ayerst Pharmaceuticals, Merck & Co., Pfizer, Seaside Therapeutics, Sepracor, Vivometrics, and MedAvante.
Drs. Lesser and Fleming have reported no relevant conflicts of interest.
An internet browser:
Internet Explorer 6.0 or newer, Firefox or Safari
Your browser must have cookies enabled and allow pop ups.
A media player:
Windows Media Player or Adobe Flash Player
Copyright © 2012 Antidote Education Company. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.
Click here to view